Pathophysiology of heparin-induced thrombocytopenia (HIT)

Platelets

Volumn 8, Issue 1, 1997, Pages 66-68

  Mikhailidis, D P ^a   Jagroop, I A ^a   Ganotakis, E S ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

CONFERENCE PAPER; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTOPENIA;

EID: 0030976539     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Dryjski M, Dryjski H. Heparin induced thrombocytopenia. Eur J Vase Endovasc Surg 1996; 11: 260-9.
2. Mikhailidis DP, Barradas MA, Jeremy JY, Gracey L, Wakeling A, Dandona P. Heparin-induced platelet aggregation in anorexia nervosa and severe peripheral vascular disease. Ear J Clin Invest 1985; 15: 313-9.
3. Mikhailidis DP, Barradas MA, Dandona P. Anorexia nervosa: a model for the investigation of platelet aggregation induced by heparin-like drugs? J Drug Dev 1989; 2: 61-5.
4. Barradas MA, Mikhailidis DP, Epemolu O, Jeremy JY, Fonseca V, Dandona P. Comparison of the platelet pro-aggregatory effect of conventional unfractionated heparins and a low molecular weight heparin fraction (CY 222). Br J Haem 1987; 67: 451-7.
5. Greenbaum RA, Barradas MA, Mikhailidis DP, Jeremy JY, Evans TR, Dandona P. Effect of heparin and contrast medium on platelet function during routine cardiac catheterisation. Cardiovasc Res 1987; 21: 878-5.
6. Mikhailidis DP, Fonseca VA, Barradas MA, Jeremy JY, Dandona P. Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172). Br J Pharmac 1987; 24: 415-24.
7. Mikhailidis DP, Barradas MA, O'Donoghue S, Dandona P. Evidence for in vivo platelet activation following the injection of conventional unfractionated heparin. Platelets 1990; 1: 189-92.
8. Mikhailidis DP, Barradas MA, Mikhailidis AM, Magnani H, Dandona P. Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function. Br J Clin Pharmac 1984; 17: 43-8.
9. Jagroop IA, Barradas MA, Mikhailidis DP. A low molecular weight heparin, nadroparin (Fraxiparine). inhibits thrombin-induced platelet shape change and does not enhance spontaneous platelet aggregation. Br J Clin Pharmacol 1996; 41: 163-5.
10. Hutton RA, Mikhailidis DP, Bernstein RM, Jeremy JY, Hughes GRV, Dandona P. Assessment of platelet function in Raynaud's syndrome. J Clin Pathol 1984; 37: 182-7.
11. 2 release: pathological implications in vascular disease. J Clin Pathol 1985; 38: 1166-71.
12. Mikhailidis DP, Ganotakis ES. Plasma albumin and platelet function: relevance to atherogenesis and thrombosis. Platelets 1996; 7: 125-37.
13. Sobel M, Adelman B. Characterization of platelet binding of heparin and other glycosaminoglycans. Thromb Res 1988; 50: 815-26.
14. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemostas 1993; 70: 554-61.
15. Keeling DM, Richards EM, Baglin TP. Platelet aggregation in response to four low molecular weight heparins and heparinoid ORG 10172 in patients with heparin-induced thrombocytopenia. Br J Haem 1994; 86: 425-6.
16. Pfueller SL, David R. Different platelet specificities of heparin dependent platelet aggregating factors in heparin-associated immune thrombocytopenia. Br J Haem 1986; 64: 149-59.
17. Mikhailidis DP, Jagroop IA, Ganotakis E, Knight CJ, Goodall AH. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996; 347: 1191.
18. Mikhailidis DP, Barradas MA. Low molecular weight heparin(oid)s. Are they the answer to heparin-associated thrombocytopenia (and thrombosis)? J Drug Dev 1989; 1: 265-73.
19. Mikhailidis DP, Jagroop IA. Unstable angina. Am Heurt J 1996; 131: 1234.
20. Cheshire NJW, Wolfe JHN, Barradas MA, Chambler AW, Mikhailidis DP. Smoking and plasma fibrinogen, lipoprotein (a), and serotonin are markers for postoperative infrainguinal graft stenosis. Eur J Vasc Endovasc Surg 1996; 11: 479-86.
21. Mikhailidis DP, Barradas MA. LMWH in vein grafts. Eur J Vasc Endovasc Surg 1995; 9: 363.
22. Wilson NV, Salisbury JR, Kakkar VV. The effect of low molecular weight heparin on intimal hyperplasia in vein grafts. Kur J Vasc Endovasc Surg 1994; 8: 60-64.
23. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low molecular-weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-8.
24. Reininger CB, Reininger AJ, Steckmeier B, Greinacher A, Lasser R, Schweiberer L. Platelet response to vascular surgery - a preliminary study on the effect of aspirin and heparin. Thromb Res 1994; 76: 79-87.
25. Reininger CB, Greinacher A, Graf J, Lasser R, Steckmeier B, Schweiberer L. Platelets of patients with peripheral arterial disease are hypersensitive to heparin. Thromb Res 1996; 81: 641-9.
26. Collins R, MacMahon S, Flather M, Baigent C, Remvig L, Mortensen S, Appleby P, Godwin J, Yusuf S, Peto R. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ 1996; 313: 652-9.